A Phase I Clinical Trial of Recombinant lnterleukin 2 and Lymphokine-Activated Killer（LAK）Cells in Patients with Hematological Malignan- cies

In this study,we initiated a phase I clinical trial of interleukin-2（IL-2）and lymphokine-activated killer（LAK） cells in 14 patients with hematological malignancies（10 acute leukemia,4 lymphoma）.They were well tolerable for IL-2 at dose of 4×10⁴u/d～5 × 10⁵u/d combining with the LAK cells induced from peripheral blood cells,cord blood cells,foetal thymus or spleen cells.The major toxicities were fever and chills.In these patients,12 were in compelet remission（CR）and one of the others was a refractory ALL who didn’t achieved a remission after 5 cycles of combinant chemotherapy based on L-ASP,DNR,6～MP,VP16,VCR and he achieved a second CR after a DOLP chemotherapy followed by one cycle of IL-2/LAK cells therapy.Another case was a relapsed Hodgkin’s disease and the toumor was obviously reduced after two cycles of IL-2/LAK cells therapy.The preliminary results indicated that infusion of IL-2 at the above doses with LAK cells is safe and may be an effective treatment for patients with acute leukemia and lymphoma after BMT or chemotherapy.